Aquestive Therapeutics, Inc. (AQST) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Aquestive Therapeutics, Inc. (AQST) Bundle
Gain mastery over your Aquestive Therapeutics, Inc. (AQST) valuation analysis using our sophisticated DCF Calculator! This Excel template comes preloaded with real AQST data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Aquestive Therapeutics, Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.6 | 45.8 | 50.8 | 47.7 | 50.6 | 50.3 | 50.1 | 49.8 | 49.5 | 49.3 |
| Revenue Growth, % | 0 | -12.85 | 10.87 | -6.2 | 6.09 | -0.52338 | -0.52338 | -0.52338 | -0.52338 | -0.52338 |
| EBITDA | -53.9 | -39.2 | -45.1 | -39.6 | 1.2 | -35.7 | -35.5 | -35.3 | -35.2 | -35.0 |
| EBITDA, % | -102.41 | -85.4 | -88.75 | -83.01 | 2.34 | -70.96 | -70.96 | -70.96 | -70.96 | -70.96 |
| Depreciation | 3.0 | 3.6 | 3.0 | 2.4 | 1.3 | 2.7 | 2.7 | 2.7 | 2.7 | 2.7 |
| Depreciation, % | 5.8 | 7.87 | 5.83 | 5.01 | 2.66 | 5.43 | 5.43 | 5.43 | 5.43 | 5.43 |
| EBIT | -56.9 | -42.8 | -48.1 | -42.0 | -.2 | -37.9 | -37.7 | -37.5 | -37.3 | -37.1 |
| EBIT, % | -108.21 | -93.26 | -94.58 | -88.02 | -0.32224 | -75.24 | -75.24 | -75.24 | -75.24 | -75.24 |
| Total Cash | 49.3 | 31.8 | 28.0 | 27.3 | 23.9 | 32.5 | 32.3 | 32.1 | 32.0 | 31.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 13.1 | 7.0 | 12.1 | 4.7 | 8.5 | 9.1 | 9.1 | 9.0 | 9.0 | 8.9 |
| Account Receivables, % | 24.96 | 15.17 | 23.84 | 9.87 | 16.75 | 18.12 | 18.12 | 18.12 | 18.12 | 18.12 |
| Inventories | 2.9 | 2.5 | 4.0 | 5.8 | 6.8 | 4.5 | 4.4 | 4.4 | 4.4 | 4.4 |
| Inventories, % | 5.43 | 5.37 | 7.94 | 12.12 | 13.38 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 |
| Accounts Payable | 12.3 | 7.1 | 8.3 | 9.9 | 8.9 | 9.4 | 9.4 | 9.3 | 9.3 | 9.2 |
| Accounts Payable, % | 23.33 | 15.46 | 16.36 | 20.86 | 17.65 | 18.73 | 18.73 | 18.73 | 18.73 | 18.73 |
| Capital Expenditure | -.7 | -.5 | -.9 | -2.5 | -1.0 | -1.2 | -1.1 | -1.1 | -1.1 | -1.1 |
| Capital Expenditure, % | -1.26 | -1.13 | -1.8 | -5.29 | -1.97 | -2.29 | -2.29 | -2.29 | -2.29 | -2.29 |
| Tax Rate, % | -3.21 | -3.21 | -3.21 | -3.21 | -3.21 | -3.21 | -3.21 | -3.21 | -3.21 | -3.21 |
| EBITAT | -62.4 | -50.1 | -61.4 | -46.4 | -.2 | -37.9 | -37.7 | -37.5 | -37.3 | -37.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -63.8 | -45.6 | -64.8 | -39.3 | -5.6 | -34.1 | -36.1 | -35.9 | -35.7 | -35.5 |
| WACC, % | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -109.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -36 | |||||||||
| Terminal Value | -221 | |||||||||
| Present Terminal Value | -95 | |||||||||
| Enterprise Value | -205 | |||||||||
| Net Debt | 9 | |||||||||
| Equity Value | -214 | |||||||||
| Diluted Shares Outstanding, MM | 61 | |||||||||
| Equity Value Per Share | -3.50 |
What You Will Get
- Real Aquestive Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Aquestive Therapeutics, Inc. (AQST).
- Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis needs.
- Instant Valuation Updates: Automatic recalculations to assess the impact of changes on the fair value of Aquestive Therapeutics, Inc. (AQST).
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed financial projections.
- Time-Saving and Accurate: Avoid the hassle of building models from scratch while ensuring precision and flexibility in your evaluations.
Key Features
- Comprehensive Historical Data: Aquestive Therapeutics’ (AQST) past financial statements and detailed forecasts.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins to suit your analysis.
- Real-Time Valuation: Observe the recalculation of Aquestive Therapeutics’ intrinsic value instantly.
- Intuitive Visualizations: Dashboard graphs present valuation outcomes and essential metrics clearly.
- Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file for Aquestive Therapeutics, Inc. (AQST).
- Step 2: Review the pre-filled financial data and forecasts for AQST.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Aquestive Therapeutics, Inc. (AQST)?
- Accuracy: Utilizes real financial data from Aquestive Therapeutics for reliable results.
- Flexibility: Tailored for users to easily adjust and experiment with various inputs.
- Time-Saving: Eliminate the need to construct a DCF model from the ground up.
- Professional-Grade: Crafted with the precision and functionality expected at the CFO level.
- User-Friendly: Designed to be accessible, even for those lacking advanced financial modeling skills.
Who Should Use This Product?
- Healthcare Students: Explore drug development processes and apply your knowledge with real-world examples.
- Researchers: Integrate advanced therapeutic models into your studies or clinical trials.
- Pharmaceutical Investors: Evaluate your investment strategies and analyze valuation metrics for Aquestive Therapeutics, Inc. (AQST).
- Market Analysts: Enhance your analysis with a customizable financial model specifically designed for biotech firms.
- Entrepreneurs in Pharma: Understand how established companies like Aquestive Therapeutics, Inc. (AQST) navigate market challenges.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Aquestive Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Aquestive Therapeutics, Inc. (AQST).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.